Study of the metabolism of the new anti-ulcer drug quiditene [(3-quinuclidyl)-di(2-thienyl)carbinol]

Thin-layer chromatography and mass spectrometry were used to study the metabolism of the new anti-ulcer drug Quiditene. After oral administration in a dose of 100 mg/kg, urine samples taken 2 h later showed no metabolites. Later samples (taken 4, 6, 8, and 10 h after administration) revealed three spots belonging to its metabolites in the chromatograms, in addition to the drug itself. Still later samples (taken 24 and 30 h after administration) revealed negligible amounts of the drug and no metabolites. The greatest amounts of metabolites were found in the urine in 6 and 8 h after administration of the drug. The structure of the metabolites was (3-quinuclidyl)-2-thienyl)ketone and its N-oxide. They were synthsized by alternate route to establish their identity and tested for anti-ulcer activity.